Provided By GlobeNewswire
Last update: Aug 26, 2025
NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
Read more at globenewswire.comNASDAQ:SNDX (12/2/2025, 3:02:43 PM)
18.5803
-0.54 (-2.82%)
Find more stocks in the Stock Screener


